InnaVirVax

About InnaVirVax

InnaVirVax, incorporated in 2008, is a French biopharmaceutical company focused on developing therapeutic solutions for diseases linked to immune dysregulation, most notably HIV/AIDS. The company was co-founded by Joël Crouzet, who serves as the CEO. His extensive background includes over two decades in pharmaceutical research and development at major firms like Rhône-Poulenc Rorer (now Sanofi Aventis) and as a director at several startups. The scientific foundation of the company stems from research conducted at Pitié-Salpêtrière Hospital by Professor Patrice Debré and Dr. Vincent Vieillard. Professor Debré is a distinguished immunologist with a vast career, including professorship at Pierre and Marie Curie Paris University, heading the clinical immunology department at Pitié-Salpêtrière Hospital, and serving as the French ambassador for the fight against HIV/AIDS.

InnaVirVax's core business revolves around the clinical development of therapeutic vaccines. The company's business model appears to be a hybrid approach, centered on advancing its internal product pipeline through clinical trials while potentially engaging in platform licensing to generate alternative revenue and mitigate risk. Its primary clients are patients within the healthcare systems of countries where clinical trials are conducted, with the ultimate customers being global healthcare providers and pharmaceutical companies upon successful commercialization. The company operates in the highly specialized biotechnology market, specifically focusing on immunotherapies. Revenue generation is projected through milestone payments from partnerships, and eventually, sales of approved therapies, with a peak sales forecast for its lead product exceeding €1 billion annually.

The company's lead product candidate is VAC-3S, a therapeutic vaccine designed to be used in conjunction with standard antiretroviral therapy (ART) for HIV-1 infected individuals. Unlike preventative vaccines, VAC-3S is an immunotherapy that aims to protect the patient's immune system. Its mechanism of action involves inducing a specific antibody response against a highly conserved region of the HIV-1 gp41 envelope protein, known as 3S. This action is intended to block the virus's ability to destroy CD4+ T-cells, which are crucial for immune function. The expected benefits for patients include the preservation and potential increase of CD4+ T-cell counts, a decrease in HIV viral reservoirs, and a reduction in the chronic inflammation associated with the infection. InnaVirVax has successfully completed a Phase I/IIa clinical trial, which demonstrated the safety and tolerability of VAC-3S. Subsequently, the company initiated a larger, randomized, double-blind, placebo-controlled Phase II trial across France, Germany, and Spain to further evaluate its efficacy and antibody response.